2 active not recruiting, 2 completed, 1 terminated, 1 withdrawn. 3 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
Follow Mediastinal Large B-cell Lymphoma: new trials by email Literature Review of Mediastinal Large B-cell Lymphoma trials Research Report on Mediastinal Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) Adaptive Bridging Radiation Therapy (ABRT) - Lymphoma, B-Cell, Relapsed Cancer | Not applicable | Completed | Massachusetts General Hospital | 10 | 2024-01-14 | 2026-10-15 |
| Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma Bridging radiation therapy, Liso-cel, Post-infusion radiation - DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | University of Nebraska | 33 | 2023-03-21 | 2026-10-08 |
| Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma 19(T2)28z1xx TRAC T cell - B-Cell Lymphoma, Large B-cell Lymphoma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2023-02-23 | 2026-04-22 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia TG-1801, Ublituximab - CLL, SLL | Phase 1 | Terminated | TG Therapeutics, Inc. | 21 | 2021-04-28 | 2024-07-31 |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Brentuximab, Bendamustine, Rituximab - Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma | Phase 2 | Withdrawn | University of Arizona | 2015-12-16 | 2017-05-19 | |
| Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) Pembrolizumab - Mediastinal Large B-cell Lymphoma, Richter Syndrome | Phase 2 | Completed | Merck Sharp & Dohme LLC | 80 | 2015-12-02 | 2023-07-27 |
Lymphoma, Follicular (4) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large B-Cell, Diffuse (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Recurrence (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Disease Attributes (2) · Lymphoma, B-Cell (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Chronic Disease (1) · Hematologic Diseases (1)
Automobiles (1) · Bendamustine Hydrochloride (1) · Brentuximab Vedotin (1) · LFB-R603 (1) · Receptors, Chimeric Antigen (1) · Rituximab (1) · pembrolizumab (1) · ublituximab (1)
Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1) · TG Therapeutics, Inc. (1) · University of Arizona (1) · University of Nebraska (1)
United States (5)
Chirayu Patel, MD (1) · Christopher R D'Angelo, MD (1) · Daniel O. Persky, MD (1) · Jae Park, MD (1)
PMID 31609651, PMID 32544980, PMID 35538512, PMID 37130017, PMID 40178467
2015 (1)